

Health




PTS Granada



Granada





Shortage of Translational and Clinical Research

25.290 articles (in 4 yrs)




101 articles with possible human clinical applications



5 were in licensed clinical use




1, and only 1, had a major impact on current medical practice




"I think you should be more explicit here in step two."

Developing medicines is a long, risky and expensive endeavour




The bottlenecks: focus on pre-competitive research



Lost in Translation



Translational Paradigm




What does industry want from Academia?


"Our main need is to identify and validate relevant biomarkers to help us to sensibly decide if we should embark on big Phase III clinical trials, which cost millions of euros to run"

Steve Averbuch, MD, Executive Director, Bristol-Myers Squibb Gregory Burke, MD, PhD, Senior VP, Novartis Renzo Canetta, MD, VP, Global Development, Bristol Myers William J. Slichenmyer, MD, VP Therapeutic Development, Pfizer Gerald Kenneaey MD Product Global Director Astra Zeneca Homer Pearce, PhD, Global Director Lilly

Industry-Academia Comparison: Translational Capabilities



How to build New Pathways from Lab to Market:



- 1. acquire, process, store, and retrieve human specimens
- 2. develop and conduct biologic surrogate endpoint analyses
- 3. develop and conduct novel imaging endpoints
- 4. write and manage INDs
- 5. write and manage complex translational clinical protocols
- 6. acquire, manage, and interpret complex clinical and biologic data

Thank you!

Any question?

